Global Settlement for About 500 Androderm Cases by Actavis

Global Settlement for About 500 Androderm Cases by Actavis

Introduction

A case management order issued by Judge Matthew Kennelly on June 29, confirmed that Actavis has agreed to settle all Androderm lawsuits filed by men claiming they suffered a heart attack, stroke or other injuries as side effects of their testosterone replacement therapy (TRT) drug. As per the order, about 500 of the testosterone claims pending in the multidistrict litigation (MDL 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation) involve Androderm.

Though no potential settlement order has been released, Judge Kennelly cited putting a stay on all Androderm claims against Actavis would allow parties to dedicate time and energy to finalize the agreement. The first bellwether trial date (August 6, 2018) for Androderm lawsuits has not been vacated yet.

Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of a federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).